Compare Wockhardt with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT vs IPCA LABS - Comparison Results

WOCKHARDT     Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT IPCA LABS WOCKHARDT/
IPCA LABS
 
P/E (TTM) x -14.2 24.1 - View Chart
P/BV x 1.1 4.6 23.9% View Chart
Dividend Yield % 0.0 0.3 1.3%  

Financials

 WOCKHARDT   IPCA LABS
EQUITY SHARE DATA
    WOCKHARDT
Mar-18
IPCA LABS
Mar-19
WOCKHARDT/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs1,0121,042 97.1%   
Low Rs532590 90.1%   
Sales per share (Unadj.) Rs355.9298.6 119.2%  
Earnings per share (Unadj.) Rs-60.335.0 -172.2%  
Cash flow per share (Unadj.) Rs-46.849.4 -94.6%  
Dividends per share (Unadj.) Rs0.013.00 0.3%  
Dividend yield (eoy) %00.4 0.4%  
Book value per share (Unadj.) Rs257.8247.1 104.3%  
Shares outstanding (eoy) m110.63126.35 87.6%   
Bonus/Rights/Conversions -ESOS-  
Price / Sales ratio x2.22.7 79.4%   
Avg P/E ratio x-12.823.3 -54.9%  
P/CF ratio (eoy) x-16.516.5 -100.0%  
Price / Book Value ratio x3.03.3 90.7%  
Dividend payout %08.6 -0.2%   
Avg Mkt Cap Rs m85,379103,108 82.8%   
No. of employees `0006.313.4 46.5%   
Total wages/salary Rs m9,3717,874 119.0%   
Avg. sales/employee Rs Th6,295.02,807.0 224.3%   
Avg. wages/employee Rs Th1,498.3585.8 255.8%   
Avg. net profit/employee Rs Th-1,066.3329.0 -324.1%   
INCOME DATA
Net Sales Rs m39,36937,732 104.3%  
Other income Rs m1,202577 208.4%   
Total revenues Rs m40,57138,309 105.9%   
Gross profit Rs m186,901 0.3%  
Depreciation Rs m1,4951,824 82.0%   
Interest Rs m2,555189 1,353.9%   
Profit before tax Rs m-2,8305,465 -51.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3,5820-   
Tax Rs m2571,042 24.7%   
Profit after tax Rs m-6,6694,422 -150.8%  
Gross profit margin %018.3 0.3%  
Effective tax rate %-9.119.1 -47.6%   
Net profit margin %-16.911.7 -144.5%  
BALANCE SHEET DATA
Current assets Rs m33,79623,778 142.1%   
Current liabilities Rs m26,91710,975 245.3%   
Net working cap to sales %17.533.9 51.5%  
Current ratio x1.32.2 58.0%  
Inventory Days Days79104 76.5%  
Debtors Days Days8966 135.4%  
Net fixed assets Rs m39,66420,368 194.7%   
Share capital Rs m553253 218.9%   
"Free" reserves Rs m27,96830,971 90.3%   
Net worth Rs m28,52231,224 91.3%   
Long term debt Rs m21,7311,409 1,542.9%   
Total assets Rs m81,62045,507 179.4%  
Interest coverage x-0.130.0 -0.4%   
Debt to equity ratio x0.80 1,689.0%  
Sales to assets ratio x0.50.8 58.2%   
Return on assets %-5.010.1 -49.7%  
Return on equity %-23.414.2 -165.1%  
Return on capital %-7.717.3 -44.3%  
Exports to sales %045.9 0.0%   
Imports to sales %016.6 0.0%   
Exports (fob) Rs mNA17,308 0.0%   
Imports (cif) Rs mNA6,266 0.0%   
Fx inflow Rs m9,80717,308 56.7%   
Fx outflow Rs m1,7896,266 28.5%   
Net fx Rs m8,01911,042 72.6%   
CASH FLOW
From Operations Rs m6844,923 13.9%  
From Investments Rs m6,302-1,563 -403.2%  
From Financial Activity Rs m-7,695-1,832 420.0%  
Net Cashflow Rs m-6641,528 -43.5%  

Share Holding

Indian Promoters % 74.5 45.9 162.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.3 11.4 20.2%  
FIIs % 7.7 25.3 30.4%  
ADR/GDR % 0.1 0.0 -  
Free float % 15.4 17.4 88.5%  
Shareholders   67,757 36,892 183.7%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT With:   ALKEM LABORATORIES  FRESENIUS KABI ONCO.  FDC LTD.  TORRENT PHARMA  STRIDES PHARMA SCIENCE  

Compare WOCKHARDT With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Momentum; Sensex Trades 186 Points Higher(12:30 pm)

Share markets in India are presently trading on a strong note. Sectoral indices are trading on a mixed note with stocks in the telecom sector.

Related Views on News

IPCA LABS at All Time High; BSE HEALTHCARE Index Up 0.5% (Market Updates)

Nov 19, 2019 | Updated on Nov 19, 2019

IPCA LABS share price has hit an all time high at Rs 1,182 (up 1.1%). The BSE HEALTHCARE Index is up by 0.5%. Among the top gainers in the BSE HEALTHCARE Index today are IPCA LABS (up 1.1%) and ABBOTT INDIA (up 0.2%). The top losers include SUN PHARMA ADV. RES. and DISHMAN CARBOGEN AMCIS LTD .

IPCA LABS Announces Quarterly Results (2QFY20); Net Profit Up 63.7% (Quarterly Result Update)

Nov 12, 2019 | Updated on Nov 12, 2019

For the quarter ended September 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 63.7% YoY). Sales on the other hand came in at Rs 12 bn (up 21.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

WOCKHARDT Announces Quarterly Results (1QFY20); Net Profit Up 57.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, WOCKHARDT has posted a net profit of Rs 369 m (up 57.2% YoY). Sales on the other hand came in at Rs 9 bn (down 14.3% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT SHARE PRICE


Nov 19, 2019 02:13 PM

TRACK WOCKHARDT

  • Track your investment in WOCKHARDT with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

WOCKHARDT - ALEMBIC LTD COMPARISON

COMPARE WOCKHARDT WITH

MARKET STATS